Industry Watch: Pharmaceutical LSD Trial Shows Progress, No Immediate Merchant Impact

Definium Therapeutics announced positive Phase 3 clinical trial results for its LSD candidate (DT120) targeting Major Depressive Disorder, noting participants cleared end-of-session checklists in an average of 5.8 hours. While this is a significant step in medical psychedelic research, this development currently poses no direct legislative or compliance changes for mushroom and psychedelic merchants on our platform, but warrants monitoring for broader industry trends.